Publication: STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
Loading...
Open/View Files
Date
2013
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Srivastava, Raghvendra M, Hyun-bae Jie, Soldano Ferrone, and Robert L Ferris. 2013. “STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P175. doi:10.1186/2051-1426-1-S1-P175. http://dx.doi.org/10.1186/2051-1426-1-S1-P175.
Abstract
Description
Other Available Sources
Research Data
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service